Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28615005 | 0.86 | EPHX1 (0.54) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL2016945 | 0.85 | CYP2C19 (0.52) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL28062414 | 0.82 | EPHX1 (0.54) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL819828 | 0.81 | KMT2A (0.58) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL819824 | 0.81 | GLS (0.46) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL14232829 | 0.80 | GLS (0.45) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL7555034 | 0.79 | EPHX1 (0.63) | EPHX1HPGDKMT2ACHRM1ALDH1A1 | |
| SCHEMBL27446150 | 0.79 | EPHX1 (0.54) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL819324 | 0.79 | MMP8 (0.51) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5196291 | 0.79 | GLS (0.53) | SMN1; SMN2GLSHPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | GLS2, GLS, GLUL | EPHX1 1980/4885CYP1A2 911/4885CYP2D6 819/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | EPHX1 1980/4885CYP1A2 911/4885CYP2D6 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.